The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Parkinson's Disease Treatments Market Research Report 2025
Synopsis
Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available.
The global Parkinson's Disease Treatments market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Parkinson's Disease Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson's Disease Treatments.
Report Scope
The Parkinson's Disease Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson's Disease Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson's Disease Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Bausch Health
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB
Segment by Type
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs
Segment by Application
Hospitals
Healthcare Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Parkinson's Disease Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Parkinson’s disease is a central nervous system syndrome which affects the motor neuron, mainly characterized by rigidity, tremor, depression, dementia, and so on. Treatment for this disease is mostly symptomatic and almost no curative treatment alternatives are available.
The global Parkinson's Disease Treatments market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Parkinson's Disease Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson's Disease Treatments.
Report Scope
The Parkinson's Disease Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson's Disease Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson's Disease Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Merck
Novartis
Teva
Boehringer Ingelheim
Impax
Abbvie
Bausch Health
Lundbeck
Sun Pharma
Wockhardt
Acadia
UCB
Segment by Type
Dopamine Agonists
Levodopa
Glutamate Antagonist
Apomorphine
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Other Drugs
Segment by Application
Hospitals
Healthcare Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Parkinson's Disease Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson's Disease Treatments Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Dopamine Agonists
1.2.3 Levodopa
1.2.4 Glutamate Antagonist
1.2.5 Apomorphine
1.2.6 COMT Inhibitors Anticholinergics
1.2.7 MAO-B Inhibitors
1.2.8 Other Drugs
1.3 Market by Application
1.3.1 Global Parkinson's Disease Treatments Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Healthcare Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Parkinson's Disease Treatments Market Perspective (2019-2030)
2.2 Parkinson's Disease Treatments Growth Trends by Region
2.2.1 Global Parkinson's Disease Treatments Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Parkinson's Disease Treatments Historic Market Size by Region (2019-2024)
2.2.3 Parkinson's Disease Treatments Forecasted Market Size by Region (2025-2030)
2.3 Parkinson's Disease Treatments Market Dynamics
2.3.1 Parkinson's Disease Treatments Industry Trends
2.3.2 Parkinson's Disease Treatments Market Drivers
2.3.3 Parkinson's Disease Treatments Market Challenges
2.3.4 Parkinson's Disease Treatments Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Parkinson's Disease Treatments Players by Revenue
3.1.1 Global Top Parkinson's Disease Treatments Players by Revenue (2019-2024)
3.1.2 Global Parkinson's Disease Treatments Revenue Market Share by Players (2019-2024)
3.2 Global Parkinson's Disease Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Parkinson's Disease Treatments Revenue
3.4 Global Parkinson's Disease Treatments Market Concentration Ratio
3.4.1 Global Parkinson's Disease Treatments Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson's Disease Treatments Revenue in 2023
3.5 Parkinson's Disease Treatments Key Players Head office and Area Served
3.6 Key Players Parkinson's Disease Treatments Product Solution and Service
3.7 Date of Enter into Parkinson's Disease Treatments Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson's Disease Treatments Breakdown Data by Type
4.1 Global Parkinson's Disease Treatments Historic Market Size by Type (2019-2024)
4.2 Global Parkinson's Disease Treatments Forecasted Market Size by Type (2025-2030)
5 Parkinson's Disease Treatments Breakdown Data by Application
5.1 Global Parkinson's Disease Treatments Historic Market Size by Application (2019-2024)
5.2 Global Parkinson's Disease Treatments Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Parkinson's Disease Treatments Market Size (2019-2030)
6.2 North America Parkinson's Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Parkinson's Disease Treatments Market Size by Country (2019-2024)
6.4 North America Parkinson's Disease Treatments Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Parkinson's Disease Treatments Market Size (2019-2030)
7.2 Europe Parkinson's Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Parkinson's Disease Treatments Market Size by Country (2019-2024)
7.4 Europe Parkinson's Disease Treatments Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Parkinson's Disease Treatments Market Size (2019-2030)
8.2 Asia-Pacific Parkinson's Disease Treatments Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Parkinson's Disease Treatments Market Size by Region (2019-2024)
8.4 Asia-Pacific Parkinson's Disease Treatments Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Parkinson's Disease Treatments Market Size (2019-2030)
9.2 Latin America Parkinson's Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Parkinson's Disease Treatments Market Size by Country (2019-2024)
9.4 Latin America Parkinson's Disease Treatments Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Parkinson's Disease Treatments Market Size (2019-2030)
10.2 Middle East & Africa Parkinson's Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2019-2024)
10.4 Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Parkinson's Disease Treatments Introduction
11.1.4 GSK Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Parkinson's Disease Treatments Introduction
11.2.4 Merck Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Parkinson's Disease Treatments Introduction
11.3.4 Novartis Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Parkinson's Disease Treatments Introduction
11.4.4 Teva Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.4.5 Teva Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Parkinson's Disease Treatments Introduction
11.5.4 Boehringer Ingelheim Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Impax
11.6.1 Impax Company Detail
11.6.2 Impax Business Overview
11.6.3 Impax Parkinson's Disease Treatments Introduction
11.6.4 Impax Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.6.5 Impax Recent Development
11.7 Abbvie
11.7.1 Abbvie Company Detail
11.7.2 Abbvie Business Overview
11.7.3 Abbvie Parkinson's Disease Treatments Introduction
11.7.4 Abbvie Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.7.5 Abbvie Recent Development
11.8 Bausch Health
11.8.1 Bausch Health Company Detail
11.8.2 Bausch Health Business Overview
11.8.3 Bausch Health Parkinson's Disease Treatments Introduction
11.8.4 Bausch Health Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.8.5 Bausch Health Recent Development
11.9 Lundbeck
11.9.1 Lundbeck Company Detail
11.9.2 Lundbeck Business Overview
11.9.3 Lundbeck Parkinson's Disease Treatments Introduction
11.9.4 Lundbeck Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.9.5 Lundbeck Recent Development
11.10 Sun Pharma
11.10.1 Sun Pharma Company Detail
11.10.2 Sun Pharma Business Overview
11.10.3 Sun Pharma Parkinson's Disease Treatments Introduction
11.10.4 Sun Pharma Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.10.5 Sun Pharma Recent Development
11.11 Wockhardt
11.11.1 Wockhardt Company Detail
11.11.2 Wockhardt Business Overview
11.11.3 Wockhardt Parkinson's Disease Treatments Introduction
11.11.4 Wockhardt Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.11.5 Wockhardt Recent Development
11.12 Acadia
11.12.1 Acadia Company Detail
11.12.2 Acadia Business Overview
11.12.3 Acadia Parkinson's Disease Treatments Introduction
11.12.4 Acadia Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.12.5 Acadia Recent Development
11.13 UCB
11.13.1 UCB Company Detail
11.13.2 UCB Business Overview
11.13.3 UCB Parkinson's Disease Treatments Introduction
11.13.4 UCB Revenue in Parkinson's Disease Treatments Business (2019-2024)
11.13.5 UCB Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
